Oncode Accelerator is a public-private partnership, with the aim of connecting partners in the Netherlands involved in the preclinical phase of the development of cancer drugs. By jointly accelerating the development of these medicines, Oncode Accelerator aims to improve the quality of life of patients and reduce the costs of developing these medicines. Various platforms are active within Oncode Accelerator in which parties work together. The innovation platform ‘Well-defined patient cohorts’ was launched on November 24 with a successful kick-off. This platform is coordinated by the UMC Utrecht and IKNL is also represented there.
In practice, it appears that treatment with new medicines is often only effective in part of the patient population for which it was developed. Oncode Accelerator wants to develop cancer treatments more efficiently and at the same time tailor candidate drugs as closely as possible to specific patient groups. Oncode Accelerator will do this by focusing on the patient earlier in the development process, using data and material from the innovation platform ‘Well-defined patient cohorts’, among other things.
Why real-time and real world data are important?
Currently, diagnoses of patients with cancer are often manually registered in the Dutch Cancer Registry (NKR) of IKNL. By automating cancer registration, we gain accelerated insight into the different patient characteristics and whether a therapy is effective in a specific patient. By using real-time, real world data, a practitioner can better determine which patients – with or without specific gene mutations – are eligible for the various clinical studies. Real-time data also makes it possible to learn during adaptive early clinical trials. This means that results are not only assessed at the end of a study, but any adjustments can be made during the study. Ultimately, the patient benefits from a more effective therapy.
Acceleration in IKNL’s ambitions
Oncode Accelerator is in line with IKNL’s ambitions to further automate the data import of the NKR and reduce manual registration. With the R(H)ONDA project, clinical data is retrieved in real-time from the electronic patient records (EPDs) using the Data Gateway of Performation. The Data Gateway is an information platform within the secure hospital environment, with which data from various EPDs is collected in a standardized manner. Within the R(H)ONDA project, data from the EPDs is automatically sent to the NKR, providing faster insight into which new resources are used in practice and what their effects are. The financing from the National Growth Fund makes it possible to scale up and accelerate this development.
Situation
In recent years, the medical specialists involved have carefully validated the clinical data that can be retrieved via the Data Gateway. This started with Hemato-Oncology (cancer of the blood, bone marrow or lymph nodes) and then solid oncology (cancer in organs, tissues and bones). At the end of 2023, the first dataset will be able to be sent to the NKR fully automatically. This development will be continued in the coming years through a phased expansion of the datasets (within the NKR Itemsets) and the scaling up of automation at more hospitals. With this we prepare the NKR to make real-time, real world data available for, among other things, the ‘Well-defined patient cohorts’ platform of Oncode Accelerator.
More information
For more information about IKNL and the Oncode Accelerator project and the innovation platform ‘Well-defined patient cohorts’, please visit the IKNL project page. More about Performation and its role in this project can be found here.
2023-11-29 08:53:28
#Oncode #Accelerator #launched #faster #development #cancer #drugs
